PIPE-791   Click here for help

GtoPdb Ligand ID: 14577

Synonyms: compound 47 [PMID: 42370792] | PIPE791
Immunopharmacology Ligand
Compound class: Synthetic organic
Comment: PIPE-791 is a brain-penetrant lysophosphatidic acid receptor 1 (LPA1R; LPAR1) antagonist [1].
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 8
Hydrogen bond donors 2
Rotatable bonds 10
Topological polar surface area 100.46
Molecular weight 477.5
XLogP 3.39
No. Lipinski's rules broken 0

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

SMILES / InChI / InChIKey
Click here for help
Canonical SMILES CC(C)C1=C(C=CC=C1)N([C@H]2CC[C@@H](CC2)C(=O)O)C(=O)NC3=CC=C(N=C3OC(F)F)OC
Isomeric SMILES O=C(NC1=C(OC(F)F)N=C(OC)C=C1)N([C@@H]2CC[C@@H](C(O)=O)CC2)C3=CC=CC=C3C(C)C
InChI InChI=1S/C24H29F2N3O5/c1-14(2)17-6-4-5-7-19(17)29(16-10-8-15(9-11-16)22(30)31)24(32)27-18-12-13-20(33-3)28-21(18)34-23(25)26/h4-7,12-16,23H,8-11H2,1-3H3,(H,27,32)(H,30,31)/t15-,16-
InChI Key QYPPPLPDAQVCOC-WKILWMFISA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

No information available.
Summary of Clinical Use Click here for help
PIPE-791 was progressed as a clinical candidate for potential to treat neuroinflammation (in MS for example) and inflammatory pain associated with chronic osteoarthritis and lumbago.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT6810245 Study of PIPE-791 for Subjects With Chronic Osteoarthritis Pain or Chronic Low Back Pain Phase 1 Interventional Contineum Therapeutics
NCT05983939 Study Evaluating Safety and Tolerability of Escalating Single and Multiple Doses of PIPE-791 and Food Effect in Healthy Volunteers Phase 1 Interventional Contineum Therapeutics
NCT07284459 Study to Evaluate the Efficacy, Safety, and Tolerability of PIPE 791 in Subjects With Idiopathic Pulmonary Fibrosis Phase 2 Interventional Contineum Therapeutics